Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2012

View Archived Issues

Johnson & Johnson presents highlights of third quarter 2012

Recent clinical data support approval of canagliflozin

Gene polymorphism linked to acute lung injury in Gram-negative sepsis

Tocilizumab shows positive effects in patients with neuromyelitis optica

Novel PI3K and mTOR inhibitors patented by Pathway Therapeutics

Abbott updates pipeline progress of third quarter 2012

New gamma-secretase modulators prepared at Pfizer

Chugai presents interim phase II results for CH-5424802

Prozymex presents new DPP-I inhibitors

CHMP recommends approval of Krystexxa

New agents for bacterial infections synthesized by Actelion Pharmaceuticals

Natco Pharma prepares new salts of anticancer agent

Actelion submits macitentan NDA

Amgen patents novel pim inhibitors

A novel marker can predict the outcome in osteosarcoma

Alnylam and Genzyme form RNAi therapeutics alliance in Asia

NXT-182 prevents neuronal apoptosis in vitro and increases neurogenesis in vivo

Health Canada approves new drug submission for Cinryze

Derma Sciences to begin phase III DSC-127 program

Astellas Pharma launches Myrbetriq in U.S.

Kaken submits application in Japan for topical antifungal agent

Eisai obtains FDA approval for Fycompa

Ono and Domain Therapeutics enter GPCR collaboration

Health Canada approves Seebri Breezhaler for COPD

Ligand to receive milestone payment from Merck & Co.

Phase I trial of Kevetrin now active

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...